



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete If Known		
			Application Number	10/700,816-Conf. #9864	
			Filing Date	November 4, 2003	
			First Named Inventor	Zuoshang XU	
			Art Unit	1635	
			Examiner Name	S. McGarry	
Sheet	1	of	4	Attorney Docket Number	UMY-038

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1*	US-5,965,722	10-12-1999	Ecker et al.	
	A2*	US-20020012968-A1	01-31-2002	Carroll et al.	
	A3*	US-20020086356-A1	07-04-2002	Tuschl et al.	
	A4*	US-6,476,205	11-05-2002	Buhr et al.	
	A5*	US-6,506,559	01-14-2003	Fire et al.	
	A6*	US-20030051263-A1	03-13-2003	Fire et al.	
	A7*	US-20030055020-A1	03-20-2003	Fire et al.	
	A8*	US-20030056235-A1	03-20-2003	Fire et al.	
	A9*	US-20030069195-A1	04-10-2003	Farrar et al.	
	A10*	US-20030108923-A1	06-12-2003	Tuschl et al.	
	A11*	US-20030144232	07-31-2003	Agami et al.	
	A12*	US-20030144239-A1	07-31-2003	Agami et al.	
	A13*	US-20040171030-A1	09-02-2004	Baker et al.	
	A14*	US-20040203145-A1	10-14-2004	Zamore et al.	
	A15*	US-20040229266-A1	11-18-2004	Tuschl et al.	
	A16*	US-20040259248-A1	12-23-2004	Tuschl et al.	
	A17*	US-20040259247-A1	12-23-2004	Tuschl et al.	
	A18*	US-20050026278-A1	02-03-2005	Tuschl et al.	
	A19*	US-20050037988-A1	02-17-2005	Zamore et al.	
	A20*	US-20050096284-A1	05-05-2005	McSwiggen	
	A21*	US-20050106731-A1	05-19-2005	Davidson et al.	
	A22*	US-20050181382-A1	08-18-2005	Zamore et al.	
	A23*	US-20050186586-A1	08-25-2005	Zamore et al.	
	A24*	US-20050191638	09-01-2005	McSwiggen	
	A25*	US-20050234006-A1	10-20-2005	Tuschl et al.	
	A26*	US-20050234007-A1	10-20-2005	Tuschl et al.	
	A27*	US-20050255086-A1	11-17-2005	Davidson et al.	
	A28*	US-20050277133-A1	12-15-2005	McSwiggen	
	A29*	US-20060009402-A1	01-12-2006	Zamore et al.	
	A30*	US-20060009408-A1	01-12-2006	Davidson et al.	
	A31*	US-20060270623-A1	11-30-2006	McSwiggen	
	A32*	US-20070003960-A1	01-04-2007	Tuschl et al.	
	A33*	US-20070003962-A1	01-04-2007	Tuschl et al.	
	A34*	US-20070003963-A1	01-04-2007	Tuschl et al.	
	A35*	US-7,241,618-A1	07-10-2007	Agami et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
	B1	WO-98/48009-A2	10-29-1998	University of Florida	
	B2	WO-01/75164-A2	10-11-2001	Whitehead Institute for Biomedical Research et al	

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known			
		Application Number	10/700,816-Conf. #9864		
		Filing Date	November 4, 2003		
		First Named Inventor	Zuoshang XU		
		Art Unit	1635		
		Examiner Name	S. McGarry		
Sheet	2	of	4	Attorney Docket Number	UMY-038

	B3	WO-02/44321-A2	06-06-2002	Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V.		
	B4	WO-03/006477-A1	01-23-2003	University of Massachusetts		
	B5	WO-03/056012-A1	07-10-2003	Cancer Research Technology Limited		
	B6	WO-04/014933-A1	02-19-2004	University of Massachusetts		
	B7	WO-05/001043-A2	01-06-2005	University of Massachusetts		
	B8	WO-05/019453-A2	03-03-2005	Sirna Therapeutics, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Abdelgany, Amir et al., "Allele-specific silencing of a pathogenic mutant acetylcholine receptor subunit by RNA interference," <i>Human Molecular Genetics</i> , Vol. 12(20):2637-2644 (2003)	
	C2	Amarzguioui, Mohammed et al., "Tolerance for mutations and chemical modifications in a siRNA," <i>Nucleic Acids Research</i> , Vol. 31(2):589-595 (2003)	
	C3	Bass, Brenda L., "The Short Answer," <i>Nature</i> , Vol. 411:428-429 (2001)	
	C4	Behndig, Anders et al., "In Vitro Photochemical Cataract in Mice Lacking Copper-Zinc Superoxide Dismutase," <i>Free Radical Biology & Medicine</i> , Vol. 31(6):738-744 (2001)	
	C5	Boutla, Alexandra et al., "Short 5'-phosphorylated double-stranded RNAs induce RNA interference in <i>Drosophila</i> ," <i>Current Biology</i> , Vol. 11:1776-1780 (2001)	
	C6	Brummelkamp, Thijn R. et al., "A System for Stable Expression of Short Interfering RNAs in Mammalian Cells," <i>Science</i> , Vol. 296:550-553 (2002)	
	C7	Brummelkamp, Thijn R. et al., "Stable suppression of tumorigenicity by virus-mediated RNA interference," <i>Cancer Cell</i> , Vol. 2:243-247 (2002)	
	C8	Caplen, Natasha J. et al., "Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference," <i>Human Molecular Genetics</i> , Vol. 11(2):175-184 (2002)	
	C9	Caplen, Natasha J. et al., "Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems," <i>PNAS</i> , Vol. 98(17):9742-9747 (2001)	
	C10	Chiu, Ya-Lin et al., "RNAi in Human Cells: Basic Structural and Functional Features of Small Interfering RNA," <i>Molecular Cell</i> , Vol. 10:549-561 (2002)	
	C11	Cleveland, Don W. et al., "From Charcot to Lou Gehrig: Deciphering Selective Motor Neuron Death in ALS," <i>Nature</i> , Vol. 2:806-819 (2001)	
	C12	Devroe, Eric et al., "Retrovirus-delivered si RNA," <i>BMC Biotechnology</i> , Vol. 2(15):1-5 (2002)	
	C13	Duprez, Laurence et al., "Pathology of the TSH Receptor," <i>Journal of Pediatric Endocrinology & Metabolism</i> , Vol. 12:295-302 (1999)	
	C14	Elbashir, Sayda M. et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <i>Nature</i> , Vol. 411:494-498 (2001)	
Examiner Signature			Date Considered

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/700,816-Conf. #9864	
			Filing Date	November 4, 2003	
			First Named Inventor	Zuoshang XU	
			Art Unit	1635	
			Examiner Name	S. McGarry	
Sheet	3	of	4	Attorney Docket Number	UMY-038

C15	Elbashir, Sayda M. et al., "Functional anatomy of siRNAs for mediating efficient RNAi in <i>Drosophila melanogaster</i> embryo lysate," <i>The EMBO Journal</i> , Vol. 20(23):6877-6888 (2001)	
C16	Elbashir, Sayda M. et al., "RNA interference is mediated by 21- and 22-nucleotide RNAs," <i>Genes & Development</i> , Vol. 15:188-200 (2001)	
C17	Flood, Dorothy G. et al., "Hindlimb Motor Neurons Require Cu/Zn Superoxide Dismutase for Maintenance of Neuromuscular Junctions," <i>American Journal of Pathology</i> , Vol. 155(2):663-672 (1999)	
C18	Fluiter, Kees et al., "Tumor Genotype-specific Growth Inhibition <i>in Vivo</i> by Antisense Oligonucleotides against a Polymorphic Site of the Large Subunit of Human RNA Polymerase II," <i>Cancer Research</i> , Vol. 62:2024-2028 (2002)	
C19	Francis, Ross et al., " <i>aph-1</i> and <i>pen-2</i> Are Required for Notch Pathway Signaling, γ -Secretase Cleavage of β APP, and Presenilin Protein Accumulation," <i>Development Cell</i> , Vol. 3:85-97 (2002)	
C20	Hammond, Scott M. et al., "An RNA-directed nuclease mediates post-transcriptional gene silencing in <i>Drosophila</i> cells," <i>Nature</i> , Vol. 404:293-296 (2000)	
C21	Hammond, Scott M. et al., "Post-Transcriptional Gene Silencing by Double-Stranded RNA," <i>Nature</i> , Vol. 2:110-119 (2001)	
C22	Hannon, Gregory J., "RNA interference," <i>Nature</i> , Vol. 418:244-251 (2002)	
C23	Hirota, Seiichi et al., "Gain-of-Function Mutations of <i>c-kit</i> in Human Gastrointestinal Stromal Tumors," <i>Science</i> , Vol. 279:577-580 (1998)	
C24	Hutvagner, György et al., "RNAi: nature abhors a double-strand," <i>Current Opinion in Genetics & Development</i> , Vol. 12:225-232 (2002)	
C25	Kawase, Makoto et al., "Exacerbation of Delayed Cell Injury After Transient Global Ischemia in Mutant Mice With CuZn Superoxide Dismutase Deficiency," <i>Stroke</i> , Vol. 30:1962-1968 (1999)	
C26	Kondo, Takeo et al., "Reduction of CuZn-Superoxide Dismutase Activity Exacerbates Neuronal Cell Injury and Edema Formation after Transient Focal Cerebral Ischemia," <i>The Journal of Neuroscience</i> , Vol. 17(11):4180-4189 (1997)	
C27	Lipardi, Concetta et al., "RNAi as Random Degradative PCR: siRNA Primers Convert mRNA into ds RNAs that are Degraded to Generate New siRNAs," <i>Cell</i> , Vol. 107:297-307 (2001)	
C28	Luyten, Ingrid et al., "Hybridization properties of base-modified oligonucleotides within the double and triple helix motif," <i>Eur. J. Med. Chem.</i> , Vol. 33:515-576 (1998)	
C29	Matz, Paul G. et al., "Cell Death After Exposure to Subarachnoid Hemolysate Correlates Inversely With Expression of CuZn-Superoxide Dismutase," <i>Stroke</i> , Vol. 31:2450-2458 (2000)	
C30	Matzuk, Martin M. et al., "Ovarian Function In Superoxide Dismutase 1 and 2 Knockout Mice," <i>Endocrinology</i> , Vol. 139(9):4008-4011 (1998)	
C31	McManus, Michael T. et al., "Gene Silencing in Mammals by Small Interfering RNAs," <i>Nature Reviews/Genetics</i> , Vol. 3:737-747 (2002)	
C32	McManus, Michael T. et al., "Gene silencing using micro-RNA designed hairpins," <i>RNA</i> , Vol. 8:842-850 (2002)	
C33	Miyagishi, Makoto et al., "U6 promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells," <i>Nature Biotechnology</i> , Vol. 19:497-500 (2002)	
C34	Moss, Eric G., "Silencing unhealthy alleles naturally," <i>TRENDS in Biotechnology</i> , Vol. 21(5):185-187 (2003)	
C35	Nykänen, Antti et al., "ATP Requirements and Small Interfering RNA Structure in the RNA Interference Pathway," <i>Cell</i> , Vol. 107:309-321 (2001)	
C36	Paddison, Patrick J. et al., "Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells," <i>Genes & Development</i> , Vol. 16:948-958 (2002)	
C37	Parrish, Susan et al., "Functional Anatomy of a dsRNA Trigger: Differential Requirement for	
Examiner Signature		Date Considered

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/700,816-Conf. #9864
		Filing Date	November 4, 2003
		First Named Inventor	Zuoshang XU
		Art Unit	1635
		Examiner Name	S. McGarry
		Attorney Docket Number	UMY-038
Sheet	4	of	4

		the Two Trigger Strands in RNA Interference," <i>Molecular Cell</i> , Vol. 6:1077-1087 (2000)	
	C38	Paul, Cynthia P. et al., "Effective expression of small interfering RNA in human cells," <i>Nature Biotechnology</i> , Vol. 29:505-508 (2002)	
	C39	Puttaparthi, Krishna et al., "Disease Progression in a Transgenic Model of Familial Amyotrophic Lateral Sclerosis Is Dependent on Both Neuronal and Non-Neuronal Zinc Binding Proteins," <i>The Journal of Neuroscience</i> , Vol. 22(20):8790-8796 (2002)	
	C40	Schwarz, Dianne S. et al., "Evidence of siRNAs Function as Guides, Not Primers, in the <i>Drosophila</i> and Human RNAi Pathways," <i>Molecular Cell</i> , Vol. 10:537-548 (2002)	
	C41	Sharp, Phillip A., "RNA interference-2001," <i>Genes & Development</i> , Vol. 15:485-490 (2001)	
	C42	Shefner, J.M. et al., "Mice lacking cytosolic copper/zinc superoxide dismutase display a distinctive motor axonopathy," <i>Neurology</i> , Vol. 53:1239-1246 (1999)	
	C43	Sijen, Titia et al., "On the Role of RNA Amplification in dsRNA-Triggered Gene Silencing," <i>Cell</i> , Vol. 107:465-476 (2001)	
	C44	Sui, Guangchao et al., "A DNA vector-based RNAi technology to suppress gene expression in mammalian cells," <i>PNAS</i> , Vol. 99(8):5515-5520 (2002)	
	C45	Taylor, J. Paul et al., "Toxic Proteins in Neurodegenerative Disease," <i>Science</i> , Vol. 296:1991-1995 (2002)	
	C46	Tuschl, Thomas et al., "Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy," <i>Molecular Interventions</i> , 2(3):158-167 (2002)	
	C47	Tuschl, Thomas et al., "Targeted mRNA degradation by double-stranded RNA in vitro," <i>Genes & Development</i> , Vol. 13:3191-3197 (1999)	
	C48	Victor, Martin et al., "HAT activity is essential for CBP-1-dependent transcription and differentiation in <i>Caenorhabditis elegans</i> ," <i>EMBO Reports</i> , Vol. 3(1):50-55 (2002)	
	C49	Wianny, Florence et al., "Specific interference with gene function by double-stranded RNA in early mouse development," <i>Nature Cell Biology</i> , Vol. 2:70-75 (1999)	
	C50	Xia, Haibin et al., "siRNA-mediated gene silencing <i>in vitro</i> and <i>in vivo</i> ," <i>Nature Biotechnology</i> , Vol. 20:1006-1010 (2002)	
	C51	Yu, Jenn-Yah et al., "RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells," <i>PNAS</i> , Vol. 99(9):6047-6052 (2002)	
	C52	Zamore, Phillip D. et al., "RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals," <i>Cell</i> , Vol. 101:25-33 (2000)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--